Potential conflict of interest: This study was funded by Janssen Research & Development, LLC. Editorial support was provided by Dr. Bethan Hahn, on behalf of Complete Medical Communications, funded by Janssen Research & Development, LLC. Dr. Fried has received research grants from, and serves as an ad hoc advisor to, Merck, Genentech, Vertex Pharmaceuticals, Tibotec/Janssen, Gilead, Bristol-Myers Squibb, Abbott, and AbbVie. Dr. Buti has participated in advisory boards and/or been a speaker for Merck, Sharpe and Dohme (MSD), Gilead, Vertex, Janssen, and Bristol-Myers Squibb. Dr. Dore has participated in an advisory committee for, and/or received financial support for research, teaching, or speaking, and/or received a travel scholarship from, Roche, Merck, Bristol-Myers Squibb, Janssen, AbbVie, and Gilead. Dr. Flisiak acts as an advisor for, and/or has received lecture fees from, Bristol-Myers Squibb, Gilead, Janssen, Merck, Novartis, Roche, and Vertex Pharmaceuticals. Dr. Ferenci was a member of an advisory board and speaker's bureau for Roche (Basel, Switzerland) and Rottapharm/Madaus (Monza, Italy), an advisor to Boehringer Ingelheim, Vertex Pharmaceuticals, Pfizer, Novartis, GlaxoSmithKline, Sanofi, and MSD, a consultant and advisor to Janssen, and receives an unrestricted research grant from Roche (Austria). Dr. Jacobson has received clinical research grants from, and/or was a consultant/advisor or member of a speaker's bureau for, Abbott, Achillion Pharmaceuticals, Anadys Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Enanta, Gilead, GlaxoSmithKline, GlobeImmune, Inhibitex, Idenix, Kadmon, Novartis, Pfizer, Pharmasset, Presidio, Roche/Genentech, Schering/Merck, Tibotec/Janssen, Vertex Pharmaceuticals, and Zymogenetics. Dr. Marcellin has received grants and/or financial support for speaking or providing expert opinion for Roche, Schering-Plough, Gilead, Bristol-Myers Squibb, Vertex Pharmaceuticals, Novartis, Pharmasset, Tibotec, MSD, Boehringer Ingelheim, Biolex, Intermune, Alios BioPharma, Abbott, Pfizer, and Zymogenetics. Dr. Sherman consults and is on the speakers' bureau for Janssen, Vertex, and Merck. He also consults for Gilead and Boehringer Ingelheim. Dr. Zeuzem consults, advises, and is on the speakers' bureau for Janssen, Vertex, and Merck. Dr. Scott and Dr. De Smedt own stock in Janssen. Dr. Gilles, Dr. Peeters, and Dr. Sekar own stock in Johnson & Johnson.
Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: The randomized PILLAR study
Article first published online: 11 OCT 2013
© 2013 by the American Association for the Study of Liver Diseases
Volume 58, Issue 6, pages 1918–1929, December 2013
How to Cite
Fried, M. W., Buti, M., Dore, G. J., Flisiak, R., Ferenci, P., Jacobson, I., Marcellin, P., Manns, M., Nikitin, I., Poordad, F., Sherman, M., Zeuzem, S., Scott, J., Gilles, L., Lenz, O., Peeters, M., Sekar, V., De Smedt, G. and Beumont-Mauviel, M. (2013), Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: The randomized PILLAR study. Hepatology, 58: 1918–1929. doi: 10.1002/hep.26641
This study was funded by Janssen Research & Development, LLC. Editorial support was provided by Dr. Bethan Hahn, on behalf of Complete Medical Communications, funded by Janssen Research & Development, LLC. M.W.F. is funded, in part, by NIH NIDDK Mid-Career Mentoring Award K24 DK066144.
- Issue published online: 26 NOV 2013
- Article first published online: 11 OCT 2013
- Accepted manuscript online: 2 AUG 2013 05:42AM EST
- Manuscript Accepted: 16 JUL 2013
- Manuscript Received: 29 JAN 2013
Additional Supporting Information may be found in the online version of this article.
|hep26641-sup-0001-suppfig1.tif||1234K||Supplementary Fig. A. Patient disposition.|
Supplementary Table A. Rates of Study Drug Discontinuation
Supplementary Table B. Rates of Viral Breakthrough and Relapse, Overall and at Selected Time Points
Supplementary Table C. Sustained Virologic Response 12 Weeks and 24 Weeks after Planned End of Treatment for the Simeprevir 150 mg and 75 mg Dose Groups and Placebo by IL28B Genotype
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.